Moderna Oncology Event October 17, 2025 © 2025 Moderna, Inc. All rights reserved. Forward-looking statements and important disclaimers This presentation being made by Moderna, Inc., and is intended solely for investors and financial analysts, and is not for promotional use. The information discussed relates to investigational candidates that have not been approved by regulatory authorities. No conclusions about the safety or efficacy of those investigational candidates should be drawn. Content is limited to ...

Core Insights - Tevogen Bio Holdings Inc. will have its Chief Information Officer, Mittul Mehta, participate in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025 [2][3] - The Startup Forum will focus on insights from venture capital leaders and early-stage innovators regarding scaling companies with Databricks [3] Company Participation - Mittul Mehta will join industry peers such as Chris Gervais, CTO of Codametrix, and Stavros Papadopoulos, CEO of TileDB, in a discussion moderated by Tony Pezzullo, Principal at SignalFire [3] - Mehta will discuss Tevogen.AI's use of advanced data and AI technologies, particularly the PredicTcell™ platform, which was developed in collaboration with Microsoft and Databricks to enhance precision immunotherapy development [3] Event Details - The Databricks DATA + AI World Tour will be held at the Sheraton Boston Hotel [4]

Core Insights - Adagene Inc. has appointed Dr. Axel Hoos as Executive Advisor, enhancing its leadership in immuno-oncology [1][2] - The company is advancing innovative antibody therapies targeting CTLA-4, aiming to improve efficacy and reduce toxicity in cancer treatment [2][6] - Dr. Hoos brings extensive experience in immuno-oncology, having previously led the development of YERVOY, the first FDA-approved immune checkpoint inhibitor [2][3][4] Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies using computational biology and artificial intelligence [5] - The company utilizes its SAFEbody precision masking technology to address safety and tolerability challenges in antibody therapeutics [6] Pipeline and Technology - Adagene's lead clinical program, ADG126, is a masked anti-CTLA-4 SAFEbody currently in phase 1b/2 studies, particularly targeting Metastatic Microsatellite-stable Colorectal Cancer [7] - The SAFEbody platform allows for tumor-specific targeting while minimizing off-tumor toxicity, enhancing the therapeutic window for antibody treatments [6][7]